Lariotx
1 known investors
Lario Therapeutics develops first-in-class precision medicines aimed at disease-modifying treatments for severe neurological disorders, including developmental and epileptic encephalopathies and Parkinson's disease. Its pipeline is built on genetically validated targets, focusing on early childhood syndromes and adult neurodegenerative conditions.
Investors · 1
Competitors · 4
by search overlap
Elicio8 shared keywordsElicio develops cancer immunotherapies including vaccines, immunomodulators, and adjuvants built on its lymph node-targeted AMP platform to activate and amplify cancer-fighting T cells. The company focuses on treating solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC).
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Applied Therapeutics7 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Latigo Bio6 shared keywordsLatigo Bio is a clinical-stage biopharmaceutical company developing non-opioid pain medicines intended to block pain transmission without addiction risk. It targets the pain management therapeutic market in the United States.
Companies competing with Lariotx for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Lariotx do?
- Lario Therapeutics develops first-in-class precision medicines aimed at disease-modifying treatments for severe neurological disorders, including developmental and epileptic encephalopathies and Parkinson's disease. Its pipeline is built on genetically validated targets, focusing on early childhood syndromes and adult neurodegenerative conditions.
- Who are Lariotx's investors?
- Lariotx's investors include Epidarex Capital.